Previous close | 48.26 |
Open | 48.35 |
Bid | 48.58 x 200 |
Ask | 48.80 x 100 |
Day's range | 48.22 - 49.06 |
52-week range | 41.75 - 98.67 |
Volume | |
Avg. volume | 1,017,836 |
Market cap | 3.251B |
Beta (5Y monthly) | 0.11 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.15 |
Earnings date | 04 May 2024 - 08 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 77.83 |
SAN DIEGO, March 06, 2024--QuidelOrtho Corporation (Nasdaq:QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received approval from Health Canada for its Triage PLGF test for laboratory use in Canada. The Triage PLGF test is a fluorescence immunoassay to be used with the small footprint Triage MeterPro® Instrument for the quantitative determination of placental growth factor ("P
SAN DIEGO, February 26, 2024--QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced that members of its management team are scheduled to participate in the 45th Annual Raymond James Institutional Investor Conference on March 5, 2024, in Orlando, FL.
SAN DIEGO, February 21, 2024--The Board of Directors (the "Board") of QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho") has made significant decisions aimed to enhance operational efficiency, drive revenue growth and deliver shareholder value.